SCHEMBL4480002

SCHEMBL4480002

O=C(Nc1ccccc1Cl)c1cccnc1F

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.64
HPGD P15428 1/20 0.64
CYP2C19 P33261 1/20 0.64
KDR P35968 1/20 0.59
PABPC1 P11940 1/20 0.58
EIF4H Q15056 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.56
HTT P42858 1/20 0.56
MCL1 Q07820 1/20 0.54
GRM4 Q14833 4/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
GAA P10253 1/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29777389 0.85 SMN1; SMN2 (0.68) CYP1A2HPGDCYP2C19KDRPABPC1
SCHEMBL975125 0.85 SMN1; SMN2 (0.68) CYP1A2HPGDCYP2C19KDRPABPC1
SCHEMBL29777391 0.85 SMN1; SMN2 (0.68) CYP1A2HPGDCYP2C19KDRPABPC1
SCHEMBL4488799 0.82 HSD17B10 (0.59) CYP1A2HPGDCYP2C19KDRSMN1; SMN2
SCHEMBL31680566 0.81 CYP1A2 (0.89) CYP1A2HPGDCYP2C19MCL1MEN1
SCHEMBL28331750 0.80 CYP1A2 (0.60) CYP1A2HPGDCYP2C19KDRPABPC1
SCHEMBL985301 0.79 L3MBTL1 (0.52) KDRPABPC1EIF4HSMN1; SMN2HTT
SCHEMBL9867402 0.79 KDR (0.70) CYP1A2HPGDCYP2C19KDRPABPC1
SCHEMBL4599740 0.78 PRKCI (0.67) HPGDKDRHTTMEN1KMT2A
SCHEMBL27782316 0.78 MAPT (0.71) KDRSMN1; SMN2HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937682-B1 MET KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
EP-1937682-A1 MET KINASE INHIBITORS Brystol-Myers Squibb Company (US) 2008-07-02 EP disclosed
WO-2007041379-A1 MET KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-12 WO disclosed
WO-2007041379-A1 MET KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-12 WO disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078140-A1 MET kinase inhibitors MET, ABL1, ERBB2 CYP1A2 2556/4885HPGD 4066/4885CYP2C19 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.